Abstract:As the important hub of many cellular signaling networks, KRAS (Kirsten rat sarcoma viral oncogene homologue) has been identified as a tumor biomarker. It is the frequently mutated oncogene in human cancers, and KRAS protein activation caused by mutations, such as G12D, has been found in many human tumors tissues. Although, there are two specific allosteric sites (AS1 and AS2) on the KRAS protein that can be used as the targets for inhibitor development, the difference of regulatory mechanisms between two individual allosteric sites still not be reported. Here, using molecular dynamics simulations combined with molecular mechanics generalized born surface area (MM/GBSA) analysis, we found that both of the inhibitors, located at AS1 and AS2, were able to reduce the binding free energy between wild type, mutant KRAS (G12/D/V/S/C) and GTP remarkably, however the effect of inhibitors on the binding free energy between wild type, mutant KRAS and GDP was limited. In addition, the degree of decrease of binding free energy between KRAS and GTP caused by inhibitors at AS2 was significantly greater than that caused by inhibitors at AS1. Further analysis revealed that both inhibitors at AS1 and AS2 were able to regulate the fluctuation of Switch Ⅰ and Switch Ⅱ to expand the pocket of the orthosteric site (GTP binding site), thereby reducing the binding of KRAS to GTP. Noteworthy there was significant differences in the regulatory preferences on Switch Ⅰ and Switch Ⅱ between two type inhibitor. The inhibitor at AS2 mainly regulated Switch Ⅱ to affect the pocket of the orthosteric site, while the inhibitor at AS1 mainly expand the pocket of the orthosteric site by regulating the fluctuation of Switch Ⅰ. Our study compared the differences between two type inhibitors in regulating the KRAS protein activity and revealed the advantages of the AS2 as the small molecule drug target, aiming to provide theoretical guidance for the research of novel KRAS protein inhibitors.

Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase

Discovery of Novel TrkA Allosteric Inhibitors: Structure-based Virtual Screening, Biological Evaluation and Preliminary SAR Studies

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with P38α MAP Kinase.

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

A Combined Computational and Experimental Approach to Studying Tropomyosin Kinase Receptor B Binders for Potential Treatment of Neurodegenerative Diseases

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12)

Identification of Pyrazine-Based TrkA Inhibitors: Design, Synthesis, Evaluation, and Computational Modeling Studies.

Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A

Computational Studies on the Binding Mechanism Between Triazolone Inhibitors and Chk1 by Molecular Docking and Molecular Dynamics

Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.

Design, Development and Evaluation of a Prodrug-Type TrkA-selective Inhibitor with Antinociceptive Effects in Vivo

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6h-pyrimido[5,4-b][1,4]oxazin-7(8h)-one Derivatives As A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.

Targeting tropomyosin receptor kinase for cancer therapy

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).

Deciphering The T790m/L858r-Selective Inhibition Mechanism Of An Allosteric Inhibitor Of Egfr: Insights From Molecular Simulations

Design, Synthesis and Biological Activity of Bicyclic Carboxamide Derivatives As TRK Inhibitors

Insights Into The Impact Of Linker Flexibility And Fragment Ionization On The Design Of Ck2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies

Molecular Dynamics and Free Energy Studies on Aurora Kinase A and Its Mutant Bound with Mln8054: Insight into Molecular Mechanism of Subtype Selectivity